Harvard Bioscience (NASDAQ:HBIO), a leading supplier of life science research tools, has a solid multi-year growth record, an exceptionally broad product and customer base, and a clean balance sheet. Despite this, shares have languished in a narrow trading range for the last 9 years, have no research coverage, and little institutional following. In recent years, growing core EPS has been masked by mounting operating losses associated with the company's Regenerative Medicine Device business unit ("RMD" or the "HART" spin-off) - which we believe has left shares meaningfully undervalued. Specifically, shares currently trade at 23x trailing 2012 reported non-GAAP EPS of $0.22. However, they trade at just 13x 2012 EPS, excluding RMD. We expect the upcoming HART spin-off to...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|